As digital health's footprint continues to grow, Bayer is leading One Drop's $40 million series B round and licensing its diabetes self-management platform for use in other disease areas. Bayer AG (Xetra:BAYN) said Tuesday it...

Edmond de Rothschild Investment Partners said the firm's partners and employees bought out the Rothschild family office's 51% majority stake, making the firm independent. The firm changed its name to Andera Partners, but said its...

Edmond de Rothschild Investment Partners said the firm's partners and employees bought out the Rothschild family office's 51% majority stake, making the firm independent. The firm changed its name to Andera Partners, but said its...

LSP closed its fifth fund, LSP 5, at a hard cap of $280 million, well above its initial target of $170 million. The firm plans to invest LSP 5 with the same strategy as previous...

JPMorgan and the Gates Foundation formed the Global Health Investment Fund (GHIF) to support late stage development of technologies against diseases that disproportionately burden low-income countries. With $94 million in committed capital from individual and...

JPMorgan and the Bill & Melinda Gates Foundation formed the Global Health Investment Fund (GHIF) to support late stage development of technologies against diseases that disproportionately burden low-income countries. With $94 million in committed capital...

Capital Royalty closed its second private equity fund, Capital Royalty Partners II, at $805 million. The firm invests worldwide in approved and commercialized healthcare products and technologies through a variety of structures including secured debt...

Capital Royalty closed its second private equity fund, Capital Royalty Partners II, at $805 million. The firm invests worldwide in approved and commercialized healthcare products and technologies through a variety of structures including secured debt...

Some of the largest public pension funds, crushed by losses in the public equity markets, are being forced to either reassess how they allocate their investments or rebalance their portfolios in order to maintain mandated...

Having gotten his hands on 215 pages of documents from Biogen Idec (NASDAQ:BIIB) under judicial order by the Delaware Chancery Court, activist investor Carl Icahn last week leveled new charges that at least one potential...